TGF-β/IL-7 Chimeric Switch Receptor-Expressing CAR-T Cells Inhibit Recurrence of CD19-Positive B Cell Lymphoma
Chimeric antigen receptor (CAR)-T cells are effective in the treatment of hematologic malignancies but have shown limited efficacy against solid tumors. Here, we demonstrated an approach to inhibit recurrence of B cell lymphoma by co-expressing both a human anti-CD19-specific single-chain variable f...
Main Authors: | Kyung-Eun Noh, Jun-Ho Lee, So-Yeon Choi, Nam-Chul Jung, Ji-Hee Nam, Ji-Soo Oh, Jie-Young Song, Han Geuk Seo, Yu Wang, Hyun Soo Lee, Dae-Seog Lim |
---|---|
Format: | Article |
Language: | English |
Published: |
MDPI AG
2021-08-01
|
Series: | International Journal of Molecular Sciences |
Subjects: | |
Online Access: | https://www.mdpi.com/1422-0067/22/16/8706 |
Similar Items
-
Targeting Cancer Stem Cells by Genetically Engineered Chimeric Antigen Receptor T Cells
by: Rowa Y. Alhabbab
Published: (2020-04-01) -
Chimeric Antigen Receptor Expressing Natural Killer Cells for the Immunotherapy of Cancer
by: Rohtesh S. Mehta, et al.
Published: (2018-02-01) -
Chimeric Antigen Receptor beyond CAR-T Cells
by: Vicky Mengfei Qin, et al.
Published: (2021-01-01) -
Killing Mechanisms of Chimeric Antigen Receptor (CAR) T Cells
by: Mohamed-Reda Benmebarek, et al.
Published: (2019-03-01) -
Chimeric Antigen Receptor (CAR) T Cell Therapy for Metastatic Melanoma: Challenges and Road Ahead
by: Tahereh Soltantoyeh, et al.
Published: (2021-06-01)